Terms: = Breast cancer AND HSP90AA1, ENSG00000080824, 3320, P07900, LAP2, HSPN, HSPCAL4, HSPCAL1, HSPCA, HSPC1, HSP90N, HSP90A, Hsp90, Hsp89, HSP86, FLJ31884
683 results:
1. The incorporation of acetylated LAP-TGF-β1 proteins into exosomes promotes TNBC cell dissemination in lung micro-metastasis.
Yu P; Han Y; Meng L; Tang Z; Jin Z; Zhang Z; Zhou Y; Luo J; Luo J; Han C; Zhang C; Kong L
Mol Cancer; 2024 Apr; 23(1):82. PubMed ID: 38664722
[TBL] [Abstract] [Full Text] [Related]
2. The hsp90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
Park M; Jung E; Park JM; Park S; Ko D; Seo J; Kim S; Nam KD; Kang YK; Farrand L; Hoang VH; Nguyen CT; La MT; Nam G; Park HJ; Ann J; Lee J; Kim YJ; Kim JY; Seo JH
Theranostics; 2024; 14(6):2442-2463. PubMed ID: 38646654
[No Abstract] [Full Text] [Related]
3. Active substance and mechanisms of Actinidia chinensis Planch for the treatment of breast cancer was explored based on network pharmacology and in silico study.
Xu Y; Yang J; Han X; Gan C; Wei X
Medicine (Baltimore); 2024 Apr; 103(15):e37829. PubMed ID: 38608062
[TBL] [Abstract] [Full Text] [Related]
4. Potential Value of hsp90α in Prognosis of Triple-Negative breast cancer.
Wang HF; Chen Y; Cao B; Pei J
Med Sci Monit; 2024 Mar; 30():e943049. PubMed ID: 38553816
[TBL] [Abstract] [Full Text] [Related]
5. Protein-folding chaperones predict structure-function relationships and cancer risk in BRCA1 mutation carriers.
Gracia B; Montes P; Gutierrez AM; Arun B; Karras GI
Cell Rep; 2024 Feb; 43(2):113803. PubMed ID: 38368609
[TBL] [Abstract] [Full Text] [Related]
6. Immunogenic cell death-related classification reveals prognosis and effectiveness of immunotherapy in breast cancer.
Zhu L; Wu Y; Zhao H; Guo Z; Bo B; Zheng L
Sci Rep; 2024 Jan; 14(1):2025. PubMed ID: 38263419
[TBL] [Abstract] [Full Text] [Related]
7. Prospects and challenges of noncoding-RNA-mediated inhibition of heat shock protein 90 for cancer therapy.
Mattoo S; Gupta A; Chauhan M; Agrawal A; Pore SK
Biochim Biophys Acta Gene Regul Mech; 2024 Mar; 1867(1):195006. PubMed ID: 38218528
[TBL] [Abstract] [Full Text] [Related]
8. Exploration of the Pharmacological Mechanism of Vitexicarpin against Triple-Negative breast cancer in Network Pharmacology.
Wu T; Xiang M; Li Y; Gao Y; Teng D; Sun M; Guo W; Zhou Y
Front Biosci (Landmark Ed); 2023 Dec; 28(12):341. PubMed ID: 38179762
[TBL] [Abstract] [Full Text] [Related]
9. Identification of molecular subtypes and prognostic model to reveal immune infiltration and predict prognosis based on immunogenic cell death-related genes in lung adenocarcinoma.
Dong Y; Yu X; Song H; Chen Q; Zheng B; Ji X; Xu M; Liu J; Sun X; Wang Q; Ren R; Lu H
Cell Cycle; 2023; 22(23-24):2566-2583. PubMed ID: 38164943
[TBL] [Abstract] [Full Text] [Related]
10. Ligand-based pharmacophore modelling, structure optimisation, and biological evaluation for the identification of 2-heteroarylthio-
Liu Y; Li C; Li Y; Zhang S; Zhang N; Bian X; Tan S
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290912. PubMed ID: 38083866
[TBL] [Abstract] [Full Text] [Related]
11. The HDAC inhibitor HFY-4A improves TUSC2 transcription to induce immunogenic cell death in breast cancer.
Yin Y; Guan X; Li G; Chen C; Duan Y; Yu Z
Toxicol Appl Pharmacol; 2023 Nov; 478():116698. PubMed ID: 37742871
[TBL] [Abstract] [Full Text] [Related]
12. Heat-shock protein 90α protects NME1 against degradation and suppresses metastasis of breast cancer.
Zhang Y; Zhao G; Yu L; Wang X; Meng Y; Mao J; Fu Z; Yin Y; Li J; Wang X; Guo C
Br J Cancer; 2023 Nov; 129(10):1679-1691. PubMed ID: 37731021
[TBL] [Abstract] [Full Text] [Related]
13. Discovery of X10g as a selective PROTAC degrader of hsp90α protein for treating breast cancer.
Jiang Q; Fu M; Tang Y; Li G; Tu G; Wu X; Wu Q; Huang X; Xu J; Liu Y; Wu L
Eur J Med Chem; 2023 Nov; 260():115690. PubMed ID: 37619298
[TBL] [Abstract] [Full Text] [Related]
14. Capsaicin binds the N-terminus of hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin).
Patwardhan CA; Kommalapati VK; Llbiyi T; Singh D; Alfa E; Horuzsko A; Korkaya H; Panda S; Reilly CA; Popik V; Chadli A
Sci Rep; 2023 Aug; 13(1):13790. PubMed ID: 37612326
[TBL] [Abstract] [Full Text] [Related]
15. Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis.
Pavlakis E; Neumann M; Merle N; Wieboldt R; Wanzel M; Ponath V; Pogge von Strandmann E; Elmshäuser S; Stiewe T
J Exp Clin Cancer Res; 2023 Aug; 42(1):203. PubMed ID: 37563605
[TBL] [Abstract] [Full Text] [Related]
16. Methods to Assess the Impact of hsp90 Chaperone Function on Extracellular Client MMP2 Activity.
Votra SD; Alsalih D; Bourboulia D
Methods Mol Biol; 2023; 2693():221-232. PubMed ID: 37540438
[TBL] [Abstract] [Full Text] [Related]
17. An Overview of Recent Findings that Shed Light on the Connection between Fat and cancer.
Pandit P; Shirke C; Bhatia N; Godad A; Belemkar S; Patel J; Zine S
Endocr Metab Immune Disord Drug Targets; 2024; 24(2):178-193. PubMed ID: 37489790
[TBL] [Abstract] [Full Text] [Related]
18. Heat shock protein 90 C-terminal inhibitor PNSA promotes anticancer immunology of CD8
Zhang A; Li M; Wang Y; Xiong Y; Zhu T; Qi X; Li J
Int Immunopharmacol; 2023 Aug; 121():110471. PubMed ID: 37356120
[TBL] [Abstract] [Full Text] [Related]
19. Synthesis of new antiproliferative 1,3,4-substituted-pyrrolo[3,2-c]quinoline derivatives, biological and in silico insights.
Mingoia F; Di Sano C; D'Anna C; Fazzari M; Minafra L; Bono A; La Monica G; Martorana A; Almerico AM; Lauria A
Eur J Med Chem; 2023 Oct; 258():115537. PubMed ID: 37329715
[TBL] [Abstract] [Full Text] [Related]
20. Timosaponin AIII promotes non-small-cell lung cancer ferroptosis through targeting and facilitating hsp90 mediated GPX4 ubiquitination and degradation.
Zhou C; Yu T; Zhu R; Lu J; Ouyang X; Zhang Z; Chen Q; Li J; Cui J; Jiang F; Jin KY; Sarapultsev A; Li F; Zhang G; Luo S; Hu D
Int J Biol Sci; 2023; 19(5):1471-1489. PubMed ID: 37056925
[TBL] [Abstract] [Full Text] [Related]
[Next]
